WO2018064122A1 - System and method for cardiac monitoring using rate-based sensitivity levels - Google Patents
System and method for cardiac monitoring using rate-based sensitivity levels Download PDFInfo
- Publication number
- WO2018064122A1 WO2018064122A1 PCT/US2017/053635 US2017053635W WO2018064122A1 WO 2018064122 A1 WO2018064122 A1 WO 2018064122A1 US 2017053635 W US2017053635 W US 2017053635W WO 2018064122 A1 WO2018064122 A1 WO 2018064122A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rate
- heart
- ecg
- thresholds
- patient
- Prior art date
Links
- 230000035945 sensitivity Effects 0.000 title claims abstract description 140
- 238000000034 method Methods 0.000 title claims abstract description 38
- 238000012544 monitoring process Methods 0.000 title claims description 27
- 230000000747 cardiac effect Effects 0.000 title description 18
- 230000002763 arrhythmic effect Effects 0.000 claims abstract description 61
- 230000001419 dependent effect Effects 0.000 claims abstract description 36
- 208000001871 Tachycardia Diseases 0.000 claims description 63
- 230000006794 tachycardia Effects 0.000 claims description 63
- 230000036471 bradycardia Effects 0.000 claims description 56
- 208000006218 bradycardia Diseases 0.000 claims description 56
- 230000000284 resting effect Effects 0.000 claims description 40
- 238000012806 monitoring device Methods 0.000 claims description 35
- 238000012545 processing Methods 0.000 claims description 31
- 230000001464 adherent effect Effects 0.000 claims description 23
- 238000012552 review Methods 0.000 claims description 21
- 238000004891 communication Methods 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 13
- 230000004044 response Effects 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 7
- 230000001960 triggered effect Effects 0.000 claims description 5
- 230000033764 rhythmic process Effects 0.000 description 20
- 230000005856 abnormality Effects 0.000 description 14
- 238000001514 detection method Methods 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 6
- 206010003119 arrhythmia Diseases 0.000 description 5
- 230000006793 arrhythmia Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 101100422260 Homo sapiens HRC gene Proteins 0.000 description 2
- NRTOMJZYCJJWKI-UHFFFAOYSA-N Titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
- A61B5/0022—Monitoring a patient using a global network, e.g. telephone networks, internet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/346—Analysis of electrocardiograms
- A61B5/349—Detecting specific parameters of the electrocardiograph cycle
- A61B5/363—Detecting tachycardia or bradycardia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0004—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by the type of physiological signal transmitted
- A61B5/0006—ECG or EEG signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/024—Measuring pulse rate or heart rate
- A61B5/02405—Determining heart rate variability
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/024—Measuring pulse rate or heart rate
- A61B5/0245—Measuring pulse rate or heart rate by using sensing means generating electric signals, i.e. ECG signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/024—Measuring pulse rate or heart rate
- A61B5/0245—Measuring pulse rate or heart rate by using sensing means generating electric signals, i.e. ECG signals
- A61B5/02455—Measuring pulse rate or heart rate by using sensing means generating electric signals, i.e. ECG signals provided with high/low alarm devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
- A61B5/1118—Determining activity level
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
- A61B5/1123—Discriminating type of movement, e.g. walking or running
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/25—Bioelectric electrodes therefor
- A61B5/251—Means for maintaining electrode contact with the body
- A61B5/257—Means for maintaining electrode contact with the body using adhesive means, e.g. adhesive pads or tapes
- A61B5/259—Means for maintaining electrode contact with the body using adhesive means, e.g. adhesive pads or tapes using conductive adhesive means, e.g. gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/25—Bioelectric electrodes therefor
- A61B5/279—Bioelectric electrodes therefor specially adapted for particular uses
- A61B5/28—Bioelectric electrodes therefor specially adapted for particular uses for electrocardiography [ECG]
- A61B5/283—Invasive
- A61B5/287—Holders for multiple electrodes, e.g. electrode catheters for electrophysiological study [EPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/333—Recording apparatus specially adapted therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/346—Analysis of electrocardiograms
- A61B5/349—Detecting specific parameters of the electrocardiograph cycle
- A61B5/361—Detecting fibrillation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2505/00—Evaluating, monitoring or diagnosing in the context of a particular type of medical care
- A61B2505/07—Home care
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/346—Analysis of electrocardiograms
- A61B5/349—Detecting specific parameters of the electrocardiograph cycle
- A61B5/352—Detecting R peaks, e.g. for synchronising diagnostic apparatus; Estimating R-R interval
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
Definitions
- the present disclosure is related in general to patient monitoring and in particular to detecting cardiac rhythm disorders.
- Cardiac monitoring - particularly ambulatory monitoring - includes long-term monitoring of ECG signals to detect various type of heart rhythm disorders.
- the amount of ECG data collected precludes human operator/technician review of the data.
- Automatic processing of the collected ECG data is utilized to detect and capture ECG segments corresponding with detected heart rhythm disorders.
- some of the ECG segments captured correspond with an actual heart rhythm disorders (i.e., a true positive event)
- other ECG segments were incorrectly identified as corresponding to a heart rhythm disorder (i.e., a false positive event).
- each captured ECG segment identified as corresponding to a heart rhythm disorder and captured represents a cost.
- That cost includes the cost of storing the captured ECG segment either on the monitoring device or externally, the cost of power required to communicate the captured ECG segment from the monitoring device to a remote monitoring center, and time required for a HCP to review the captured ECG episode and determine whether action is required.
- it is beneficial to reduce the ECG segments incorrectly identified as corresponding to a heart rhythm disorder (i.e., minimize false positive events).
- it is also important to ensure that heart rhythm disorders are detected and corresponding ECG segments captured and provided to a human HCP for review (i.e., avoid missing detection of positive events, or false negative).
- a method of detecting arrhythmic electrocardiogram (ECG) segments comprises defining a plurality of threshold heart rates and rate-dependent sensitivity levels for detecting arrhythmic ECG episodes, wherein more clinically relevant heart rates are assigned rate-dependent sensitivity levels with higher sensitivities.
- ECG signals associated with a patient are monitored using a monitoring device and the monitored ECG signals are processed using the plurality of threshold heart rates and rate-dependent sensitivity levels to detect and capture arrhythmic ECG segments.
- a system for monitoring electrocardiogram (ECG) signals and detecting arrhythmic ECG episodes comprises a monitoring device and a processing module.
- the monitoring device includes one or more electrodes and sensing circuitry for monitoring ECG signals associated with a patient.
- the processing module is configured to receive the monitored ECG signal, and to utilize the plurality of heart-rate thresholds and rate-dependent sensitivity levels to detect and capture arrhythmic ECG segments.
- a medical device comprises a sensing unit, a memory unit, and a processor.
- the sensing unit is capable of monitoring an electrocardiogram (ECG) signal of the patient.
- ECG electrocardiogram
- the memory unit stores a plurality of heart-rate thresholds and rate-dependent sensitivity levels, and the processor processes the monitored ECG signal to detect and capture arrhythmic ECG segments based on the plurality of heart-rate thresholds and rate-dependent sensitivity levels.
- FIG. 1 illustrates a schematic view of a monitoring and/or treatment system that monitors electrocardiogram (ECG) signals and communicates ECG episodes representative of detected arrhythmias to a monitoring center according to an embodiment of the present invention.
- ECG electrocardiogram
- FIGS. 2a and 2b are charts illustrating rate-dependent sensitivity and specificity thresholds, respectively, utilized for arrhythmia detection according to an embodiment of the present invention.
- FIG. 3 is a flowchart that illustrates a method of personalizing heart-rate thresholds and rate -based sensitivity/specificity based on received patient data according to an embodiment of the present invention.
- FIG. 4 is a flowchart that illustrates a method of personalizing heart-rate thresholds and rate -based sensitivity/specificity based on received patient data according to another embodiment of the present invention.
- FIG. 5 is a data structure utilized at remote monitoring center according to an embodiment of the present invention to allow a health care professional (HCP) to filter/search through captured ECG segments.
- HCP health care professional
- FIG. 6 is an exploded view of an adherent monitoring device utilized to monitor and detect ECG episodes according to an embodiment of the present invention.
- FIG. 7 is a perspective view of an insertable monitoring device utilized to monitor and detect ECG episodes according to an embodiment of the present invention.
- the present invention provides a system and method of monitoring and processing electrocardiogram (ECG) signals to automatically capture clinically relevant ECG segments for subsequent review.
- ECG electrocardiogram
- rate-dependent sensitivity/specificity levels are assigned based on the clinical relevance of the underlying cardiac abnormality, with the rate-dependent sensitivity assigned a higher level for more clinically relevant cardiac conditions such as high-rate tachycardia or low-rate bradycardia.
- the rate-based sensitivity/specificity levels utilized by the monitoring device are based on one or more patient characteristics, such as age, basal/resting heart rate, etc.
- the sensitivity/specificity profiles are programmable by a health care professional (HCP) - either at the onset of the prescribed monitoring period or during the monitoring period in response to the diagnostic yield of the monitoring device.
- HCP health care professional
- sensitivity is a measure of the proportion of positive events that are correctly identified as such, otherwise referred to as the true positive rate.
- Specificity is the reciprocal of sensitivity and is a measure of the proportion of negative events that are correctly identified as such, otherwise referred to as the true negative rate.
- sensitivity quantifies the avoiding of false negatives while specificity quantifies the avoiding of false positives. Utilizing a higher sensitivity level reduces the risk of missing a true positive event (e.g., arrhythmia), but at a cost of identifying more false positive events (i.e., low specificity, normal sinus rhythm incorrectly identified as arrhythmic).
- utilizing a high specificity reduces the number of false positive events (i.e., ECG segments incorrectly identified as arrhythmic), but at a cost of potentially failing to identify a true positive event (e.g., arrhythmia).
- sensitivity and specificity are reciprocal in nature, most embodiments are described with respect to a rate-based sensitivity level, but it should be understood that a rate- based specificity level may similarly be utilized.
- monitoring devices detect a positive event (e.g., tachycardia, bradycardia, etc.) when the monitored heart rate in X out of the last Y beats (e.g., 13 out of the last 19 beats) exceeds a heart rate threshold (e.g., 130 BPM, 150 BPM, 165 BPM, or 180 BPM).
- a positive event e.g., tachycardia, bradycardia, etc.
- a heart rate threshold e.g. 130 BPM, 150 BPM, 165 BPM, or 180 BPM.
- the value of the variables X and Y in this case determine the sensitivity level, and can be modified either alone or in combination to increase or decrease the sensitivity.
- the sensitivity can be increased by utilizing a smaller ratio of X to Y, and is decreased by increasing the ratio of X to Y.
- X 10 and Y equal to 20 requires that 10 beats out of 20 must exceed the heart rate threshold to trigger capture of the ECG segment.
- the sensitivity level is increased if X is set equal to 5 and Y remains equal to 20, such that only 5 beats out of 20 must exceed the heart rate threshold to trigger capture of the ECG segment - and is therefore more sensitive.
- the sensitivity level is decreased if X is set equal to 15 and Y is set equal to 18, such that now 15 beats out of 18 must exceed the heart rate threshold to trigger capture of the ECG segment.
- Specificity may also be defined in terms of the variables X and Y, but whereas sensitivity is increased by lowering the value of the ratio X/Y, specificity is increased by increasing the value of the ratio X/Y.
- the present disclosure describes the sensitivity/specificity in terms of level (e.g., high, medium, low) rather than in terms of the value of X/Y utilized to determine the desired sensitivity/specificity level.
- FIG. 1 illustrates a patient P and a monitoring system 10, according to one or more embodiments of the present disclosure for monitoring cardiac activity.
- Patient P comprises a midline M, a first side SI, for example a right side, and a second side S2, for example a left side.
- Monitoring system 10 comprises a patient medical device 100, gateway 102, and remote monitoring center 106.
- patient medical device 100 is an adherent device that attaches to the skin of the patient, but in other embodiments may be an implantable device, an insertable device, an injectable device, or a wearable device such as a Holter monitor (collectively referred to as a medical device).
- a medical device is an adherent device that attaches to the skin of the patient, but in other embodiments may be an implantable device, an insertable device, an injectable device, or a wearable device such as a Holter monitor (collectively referred to as a medical device).
- a medical device has advantages and disadvantages, in terms of battery life, memory, communication
- injectable devices have limited on-board memory that may be insufficient to store all detected arrhythmic ECG segments. As a result, older arrhythmic ECG segments may be overwritten by newer ECG segments. Utilizing rate-based sensitivity/specificity levels identifies more clinically relevant arrhythmic ECG segments to be captured, and therefore better utilizes the limited on-board memory associated with an injectable device. Likewise, some adherent devices utilize wireless/cellular communication to communicate arrhythmic ECG segments to a remote monitoring center. However, there is a cost of communicating detected arrhythmic ECG segments, which includes the time required for a HCP to review each communicated ECG segment.
- medical device 100 is described herein as providing a monitoring function, but in other embodiments may be configured to provide treatment as well.
- Medical device 100 can be adhered/injected/inserted to a patient P at many locations, for example thorax T of patient P.
- the device may adhere to one side of the patient, from which side data can be collected.
- a benefit of utilizing an adherent device, implantable, or injectable device is that it may be utilized to collect physiological data from the patient while the patient goes about normal day- to-day activities outside of a hospital setting.
- Medical device 100 may monitor a number of physiological parameters associated with patient P, including electrocardiogram (ECG) signals utilized to detect rhythm abnormalities such as tachycardia and/or bradycardia as well as activity level data, posture, bio-impedance, etc. Analysis of the ECG signals to detect rhythm abnormalities may be done locally by medical device 100 or remotely by gateway 102 and/or remote monitoring center 106 (or similar platform separate from medical device 100).
- ECG electrocardiogram
- heart-rate thresholds and rate-dependent sensitivity/specificity levels are utilized to detect rhythm abnormalities such as a tachycardia/bradycardia.
- medical device 100 captures/stores an ECG segment corresponding with the detected abnormality.
- the captured ECG segment is subsequently transmitted to remote monitoring center 106 for review by a human HCP.
- Communication of the captured ECG segment may be immediate, or may be delayed for a period of time (i.e., until it is possible/cost effective to communicate the stored ECG segment).
- the HCP may verify the detected rhythm abnormality and take appropriate steps (e.g., prescribe treatment).
- monitored ECG signals are communicated to an external processor such as gateway 102 or remote monitoring center 106 for analysis and detection of rhythm abnormalities.
- gateway 102 and/or remote monitoring center 106 utilizes heart-rate thresholds and rate-dependent sensitivity/specificity thresholds to detect rhythm abnormalities such as a tachycardia/bradycardia.
- rhythm abnormalities such as a tachycardia/bradycardia.
- an ECG segment corresponding with the detected abnormality is captured and stored for subsequent review by a HCP.
- medical device 100 communicates wirelessly with remote center 106.
- the communication may occur directly (via a cellular or Wi-Fi network), or indirectly through intermediate device or gateway 102.
- ECG signals monitored by medical device 100 are communicated in their entirety to remote center 106 for analysis.
- medical device 100 processes the monitored ECG signals locally using heart-rate thresholds and rate-dependent sensitivity/specificity thresholds to detect rhythm abnormalities and stores/captures ECG segments corresponding with detected abnormalities.
- gateway 102 comprises components of the zLinkTM, a small portable device similar to a cell phone that wirelessly transmits information received from medical device 100 to remote monitoring center 106.
- the gateway 102 may consist of multiple devices, which can communicate wired or wirelessly with remote center 106 in many ways, for example with a connection 104 which may comprise an Internet connection and/or with a cellular connection.
- Remote center 106 may comprise a hosted application for data analysis and storage that also includes a website, which enables secure access to physiological trends and clinical event information for interpretation and diagnosis.
- Remote center 106 may further or alternatively comprise a back-end operation where physiological data from adherent device 100 are read by human experts to verify accuracy.
- Reports may then be generated at remote monitoring center 106 for communication to the patient's physician or care provider.
- remote monitoring center 106 may communicate/push heart-rate thresholds and/or rate-dependent sensitivity/specificity thresholds to medical device 100, either to program/initialize medical device 100 or update the values stored by medical device 100.
- monitoring system 10 comprises a distributed processor system with at least one processing module (not shown) included as part of adherent device 100, at least one processor 102P of gateway 102, and at least one processor 106P at remote center 106, each of which processors can be in electronic communication with the other processors.
- At least one processor 102P comprises a tangible medium 102T
- at least one processor 106P comprises a tangible medium 106T.
- Remote processor 106P may comprise a backend server located at the remote center.
- Physiological parameters - including ECG samples - monitored by medical device 100 may be analyzed by one or more of the distributed processors included as part of medical device 100, gateway 102, and/or remote monitoring center 106.
- FIGS. 2a and 2b are charts illustrating rate-dependent sensitivity and specificity thresholds, respectively, utilized for arrhythmia detection according to an embodiment of the present invention.
- the charts illustrate the reciprocal relationship between sensitivity and specificity, and the assumption that higher rate tachycardia events are more clinically relevant than lower rate tachycardia events (and that lower rate bradycardia events are more clinically relevant than higher rate bradycardia events).
- FIGS. 1 are charts illustrating rate-dependent sensitivity and specificity thresholds, respectively, utilized for arrhythmia detection according to an embodiment of the present invention.
- the charts illustrate the reciprocal relationship between sensitivity and specificity, and the assumption that higher rate tachycardia events are more clinically relevant than lower rate tachycardia events (and that lower rate bradycardia events are more clinically relevant than higher rate bradycardia events).
- a plurality of heart-rate thresholds are selected (e.g., bradycardia thresholds at 30 BPM, 40 BPM, and 50 BPM, and tachycardia thresholds at 130 BPM, 140 BPM, and 150 BPM), although in other embodiments additional or fewer threshold values may be utilized, and threshold values may be selected at any heart rate desired.
- heart-rate thresholds are selected based on one or more patient characteristics or one or more physiological parameters monitored with respect to the patient. Similarly, additional or fewer heart-rate thresholds may be utilized each having an assigned sensitivity/specificity level.
- rate-dependent sensitivity levels are defined for both bradycardia and tachycardia event detection.
- a higher rate tachycardia may be more clinically significant than a lower rate tachycardia.
- higher rate tachycardia thresholds are assigned higher sensitivity levels.
- a tachycardia event exceeding 150 BPM (referred to as a tachyl50) is assigned a higher sensitivity than a tachycardia exceeding 140 BPM (i.e., tachyl40), which in turn is assigned a higher sensitivity level than a tachycardia exceeding 130 BPM (i.e. tachyl30).
- the higher sensitivity associated with higher rate tachycardia threshold reduces the risk of missing a true positive event (e.g., tachyl50 event), but at a cost of identifying more false positive tachyl50 events.
- the lower sensitivity level associated with lower rate tachycardia thresholds reduces false positives associated with - at least in this embodiment - clinically less relevant tachycardia events.
- bradycardia event less than 30 BPM (referred to as a brady30 event) is assigned a higher sensitivity than a bradycardia event less than 40 BPM (i.e., brady40), which in turn is assigned a higher sensitivity than a bradycardia less than 50 BPM (i.e. brady50).
- FIG. 2b illustrates the reciprocal relationship between sensitivity and specificity.
- the highest rate tachycardia (tachyl50) is assigned a specificity that is lower than the specificity assigned to tachycardia exceeding 140 BPM (tachyl40), which in turn is assigned a lower specificity than a tachycardia exceeding 130 BPM (i.e. tachyl30).
- bradycardia event less than 30 BPM (referred to as a brady30 event) is assigned a lower specificity than a bradycardia less than 40 BPM (i.e., brady40), which in turn is assigned a lower specificity than a bradycardia less than 50 BPM (i.e. brady50).
- brady40 a bradycardia less than 40 BPM
- brady50 i.e. brady50
- the lower specificity associated with lower rate bradycardia events increases the risk of a false positive event (e.g., normal sinus rhythm classified incorrectly as a brady30 event), but minimizes the risk of failing to identify a brady30 event.
- FIG. 3 is a flowchart that illustrates a method of personalizing arrhythmic thresholds and rate -based sensitivity/specificity based on received patient data according to an embodiment of the present invention.
- Patient data may include a variety of characteristics related to the patient, including patient age, weight, sex, resting heart rate, etc.
- the embodiment shown in FIG. 3 utilizes patient data (e.g., patient age in this example) as an input for personalizing arrhythmic thresholds, however, it should be understood that in other embodiments various other patient characteristics may be utilized either alone or in combination with patient age to personalize arrhythmic thresholds.
- patient data is received as an input.
- the input is related to the age of the patient, but as discussed above may include other patient data.
- the input may be received by the monitoring device directly, or may be received external to the monitoring device (e.g., remote monitoring center) capable of updating the heart-rate thresholds and/or rate-based sensitivity/specificity of the monitoring device.
- heart-rate thresholds are defined based on the received patient data.
- patient age is utilized to personalize the heart-rate thresholds utilized to analyze ECG signals.
- Table 1 illustrates the personalization of the heart-rate thresholds according to an embodiment of the present invention.
- High Rate Tachycardia e.g., Age Predicted Higher Sensitivity Level (e.g., X/Y Maximal Heart Rate + 5 BPM) small)
- Medium Rate Tachycardia e.g., Age Medium Sensitivity Level (e.g., X/Y Predicted Maximal Heart Rate - 10) BPM) medium
- Low Rate Tachycardia e.g., Age Predicted Lower Sensitivity Level (e.g., X/Y Maximal Heart Rate - 30 BPM) high)
- Low Rate Bradycardia e.g., Min(Max(Age- Higher Sensitivity Level (e.g., X/Y 25,15),60) BPM) small
- Medium Rate Bradycardia e.g., Medium Sensitivity Level (e.g., X/Y Min(Max(Age-15,15),60) BPM) medium
- Medium Sensitivity Level e.g., X/Y Min(Max(Age-15,15),60) BPM
- High Rate Bradycardia e.g., Min(Max(Age- Lower Sensitivity Level (e.g., X/Y 5,15),60) BPM high)
- the heart-rate thresholds defined with respect to tachycardia detection is based on the age-predicted maximal heart rates.
- the highest rate tachycardia threshold is assigned the highest sensitivity level.
- the sensitivity level is lowered.
- the heart-rate thresholds defined with respect to tachycardia detection the patient' s age is utilized to select an age-predicted maximal heart rate, which in turn is utilized to select the various tachycardia heart-rate thresholds.
- the patient' s age is used to directly to determine the various bradycardia heart-rate thresholds.
- the low rate bradycardia threshold is defined as (Min(Max(Age-25,15),60) BPM).
- the equation is defined as (Min(Max(70-25,15),60) BPM), which corresponds to a low-rate bradycardia threshold of forty-five (45) BPM.
- the equation would correspond to a low-rate bradycardia threshold of fifteen (15) BPM.
- other patient characteristics may be utilized to define the various heart-rate thresholds.
- the personalized arrhythmic thresholds are communicated to the monitoring device.
- medical device 100 calculates the personalized arrhythmic thresholds according to calculations such as those shown in Table 1.
- personalized arrhythmic thresholds are provided to the computer/device responsible for processing ECG signals from the corresponding patient.
- ECG data is monitored by medical device 100.
- the monitored ECG signals are processed/analyzed using the personalized heart-rate thresholds and rate-based sensitivity levels defined based on the patient data to detect arrhythmic ECG segments.
- processing/analysis of ECG data may be done locally by medical device 100 or remotely - for example at gateway 102 or remote monitoring center 106.
- arrhythmic ECG segments - if processed locally by medical device 100 - are communicated to remote monitoring center 106 for review by a HCP.
- Utilization of patient data to personalize heart-rate thresholds and rate -based sensitivity/specificity thresholds results in a higher percentage of clinically relevant ECG segments being provided to remote monitoring center for review.
- a benefit of this approach is that fewer ECG segments are provided to the remote monitoring center for review, but while retaining sensitivity/specificity balance that ensures clinically relevant ECG segments are reviewed by a HCP.
- FIG. 4 is a flowchart that illustrates another method of personalizing heart-rate thresholds and rate -based sensitivity/specificity based on received patient data according to an embodiment of the present invention.
- patient data is based on a physiological parameter monitored by medical device 100.
- the embodiment shown in FIG. 4 monitors basal/resting heart of the patient, and determines the personalized arrhythmic thresholds and rate -based sensitivity levels based on the monitored basal/resting heart rate.
- monitoring device determines whether the patient is at rest. This determination may be based on one or more monitored physiological parameters (e.g., activity level, posture, sleep status, etc.), or may be based on external factors such as time of day, patient location, or patient input). These inputs may be utilized alone or in combination with one another. For example, in one embodiment patient activity level and/or posture is determined based on accelerometer measurements taken by medical device 100. If the accelerometer measurements indicate the patient is not moving, or is in a prone position, then a determination is made that the patient is at rest.
- monitored physiological parameters e.g., activity level, posture, sleep status, etc.
- external factors such as time of day, patient location, or patient input.
- a determination that the patient is at rest may take into account the local time, and utilize a time (e.g., between 12:00 and 4:00 in the morning) in which it is suspected that the patient is sleeping to measure the basal/resting heart rate of the patient.
- input is received from the patient or physician indicating the patient is in a rest state.
- a patient being outfitted with a medical device 100 at the physician's office may indicate a resting state during which a basal/resting heart rate may be measured.
- additional calibration steps may be utilized.
- the patient may be instructed to remain sitting for a period of time (e.g., 5 minutes), then instructed to walk for a period of time (e.g., 5 minutes), following by another period of sitting.
- Average heart rate data is collected during these periods of time in order to determine the basal/resting heart to be utilized on a patient-by-patient basis.
- the basal/resting heart rate of the patient is measured.
- the heart rate of the patient is monitored for a period of time and averaged to determine the basal/resting heart rate of the patient.
- heart-rate thresholds and/or rate-based sensitivity levels are defined based on the monitored basal/resting heart rate of the patient.
- Table 2 illustrates the personalization of the heart rate thresholds (i.e., arrhythmic thresholds) and corresponding rate -based sensitivity/specificity levels according to an embodiment of the present invention.
- High Rate Tachycardia e.g., Basal/Resting Higher Sensitivity Level (e.g., X/Y Heart Rate + 110 BPM) small
- Medium Rate Tachycardia e.g., Medium Sensitivity Level (e.g., X/Y Basal/Resting Heart Rate + 100 BPM) medium
- Low Rate Tachycardia e.g., Basal/Resting Lower Sensitivity Level (e.g., X/Y Heart Rate + 90 BPM) high
- Basal/Resting Lower Sensitivity Level e.g., X/Y Heart Rate + 90 BPM
- Low Rate Bradycardia e.g., Basal/Resting Higher Sensitivity Level (e.g., X/Y Heart Rate - 40 BPM) small
- Basal/Resting Higher Sensitivity Level e.g., X/Y Heart Rate - 40 BPM
- Medium Rate Bradycardia e.g., Medium Sensitivity Level (e.g., X/Y Basal/Resting Heart Rate - 30 BPM) medium
- Medium Sensitivity Level e.g., X/Y Basal/Resting Heart Rate - 30 BPM
- High Rate Bradycardia e.g., Basal/Resting Lower Sensitivity Level (e.g., X/Y Heart Rate - 20 BPM high)
- the heart-rate thresholds defined with respect to tachycardia detection are based on the monitored basal/resting heart rate monitored with respect to the patient.
- the highest rate tachycardia is assigned the highest sensitivity level.
- the sensitivity level is lowered.
- the monitored basal/resting heart rate is similarly employed in the calculation of the various bradycardia thresholds.
- the low rate bradycardia threshold is defined as Basal/Resting Heart Rate - 40 BPM.
- the low rate bradycardia threshold is set equal to 25 BPM.
- medical device 100 measures the basal/resting heart rate of the patient, and therefore may determine the thresholds utilized locally based on the monitored basal/resting heart rate. In embodiments in which processing of the ECG signals is done remotely, then monitoring device may similarly communicate the measured basal/resting heart rate to the remote monitoring center to define the arrhythmic thresholds and rate-based sensitivity levels.
- ECG data is monitored by medical device 100.
- the monitored ECG signals are processed/analyzed using the personalized arrhythmic thresholds and rate -based sensitivity levels defined based on the measured basal/resting heart rate.
- processing/analysis of ECG data may be done locally by medical device 100 or remotely - for example at gateway 102 or remote monitoring center 106.
- arrhythmic ECG segments - if processed locally by medical device 100 - are communicated to remote monitoring center 106 for review by a HCP. Utilization of measured basal/resting heart rate of the patient to personalize heart-rate thresholds and rate-based sensitivity/specificity thresholds results in a higher percentage of clinically relevant ECG segments being provided to remote monitoring center for review.
- a benefit of this approach is that clinically relevant ECG segments are reviewed by a HCP, or reviewed with higher-priority by the HCP.
- arrhythmic ECG segments are not communicated to a remote monitoring center but are instead stored locally.
- implantable devices may not utilize communicate arrhythmic ECG segments, but rather may store captured segments until such time the segments can be downloaded for review.
- memory is limited, and may result in older stored ECG segments being overwritten by newer segments.
- identification of ECG segments as more clinically relevant than others allows for those more clinically relevant ECG segments to avoid being overwritten. For example, triggering of an ECG segment with a lower sensitivity level results in a more clinically relevant ECG segment than one triggered (assuming the same heart-rate threshold) using a higher sensitivity level. As a result, the ECG segment captured using the lower sensitivity level may be retained in memory over other, less clinically relevant ECG segments.
- FIG. 5 is a data structure utilized at remote monitoring center according to an embodiment of the present invention to allow a HCP to filter/search through captured ECG segments.
- Each data record is comprised of a captured ECG segment, along with additional information or data tags that provide additional information to the HCP regarding the captured ECG segment.
- FIG. 5 is a data structure utilized at remote monitoring center according to an embodiment of the present invention to allow a HCP to filter/search through captured ECG segments.
- Each data record is comprised of a captured ECG segment, along with additional information or data tags that provide additional information to the HCP regarding the captured ECG segment.
- tags include corresponding heart-rate threshold utilized to trigger capture of the ECG segment (e.g., brady30, tachyl50, etc.), rate-based sensitivity level (e.g., high sensitivity, low sensitivity, etc.), ratio of beats exceeding the heart-rate threshold (e.g., 15 out of 20 beats), trigger condition (e.g., tachycardia, bradycardia, etc.), patient activity level (e.g., active, at rest), and ECG segment to be reviewed.
- Additional data/ information provided in the tags associated with each captured ECG segment allows a HCP to filter/search ECG segments based on these tags. For example, a HCP such as a physician may be most interested in tachycardia conditions detected while a patient is at rest, and could therefore use the activity level tag in combination with the trigger condition field to identify ECG segments relevant to the reviewing HCP.
- the tags associated with the first ECG segment describe the heart-rate threshold utilized to trigger capture of the ECG segment as 130 BPM.
- the rate-based sensitivity level is identified as being low- sensitivity (e.g., 15 beats out of 20 required to exceed the heart-rate threshold). In one embodiment, this may include a numerical representation of the sensitivity (e.g., X/Y) or simply a description of the rate-based sensitivity level (e.g., high, medium, low).
- the first record lists the ratio of beats measured as exceeding the arrhythmic threshold (e.g., 17 beats out of 20), even though the sensitivity level only required 15 beats out of 20.
- triggering thresholds using relatively high sensitivity thresholds such as that shown with respect to the third ECG segment, in which only 5 beats out of 20 are required to trigger capture of the ECG segment, but in fact 15 beats out of 20 were measured as exceeding the threshold.
- the trigger condition e.g., tachycardia, bradycardia, etc.
- other information such as other monitored physiological parameters (e.g., activity level of the patient at the time the ECG segment was captured).
- activity level of the patient may be important to a HCP reviewing tachycardia events, wherein lower rate tachycardia events detected while a patient is active may be less clinically relevant than lower rate tachycardia events detected while a patient is at rest.
- a benefit of including one of more of these tags with the captured ECG segment is that it allows the HCP reviewing the captured ECG segments to focus on those of potential highest importance, as opposed to reviewing the ECG segments in the order they occur.
- the records may be coded according to relevance to aid a HCP in reviewing the captured ECG segments. This may include automatic ordering of the ECG segments according to a predetermined criteria (e.g., high sensitivity ECG segments first, ordered by the rest state of the patient and the ratio of beats exceeding the threshold), or may include color-coding of the ECG segments according to clinical relevance.
- a predetermined criteria e.g., high sensitivity ECG segments first, ordered by the rest state of the patient and the ratio of beats exceeding the threshold
- utilizing a data structure such as that shown in Figure 5 improves the ability of a HCP to sort and filter ECG segments to review those holding the most clinical relevance.
- it may be advantageous to capture all potentially relevant ECG segments i.e., increase rate-based sensitivities
- FIG. 6 is an exploded view, respectively, of monitoring device 600 with rate- based sensitivity detection, according to one or more embodiments of the present disclosure.
- monitoring device 600 is an adherent device, but as described above may also be implemented as an implantable device, an injectable device, or similar wearable device.
- adherent device 600 includes adherent tape 610T, electrodes 612A, 612B, 612C, 612D with gels 614A, 614B, 614C, 614D, printed circuit board (PCB) 620, flexible connected 622A, electrical components/sensors 630 mounted on PCB 620, batteries 650, electronics housing cover 660, and flexible cover 662.
- PCB printed circuit board
- Adherent device 600 comprises at least two electrodes - although the embodiment shown in FIG. 6 includes electrodes 612A, 612B, 612C and 612D.
- Adherent device 600 may comprise a maximum dimension, for example a maximum length from about 4 to 10 inches, a maximum thickness along a profile of the device from about 0.2 inches to about 0.6 inches, and a maximum width from about 2 to about 4 inches.
- the adherent patch 600 comprises a first side, or a lower side 610A, that is oriented toward the skin of the patient when placed on the patient.
- the adherent patch 600 may also comprise a tape 610T which is a material, preferably breathable, with an adhesive (not shown) to adhere to patient P.
- Electrodes 612A, 612B, 612C and 612D are affixed to adherent patch 600. In many embodiments, at least four electrodes are attached to the patch. Gels 614A, 614B, 614C and 614D can each be positioned over electrodes 612A, 612B, 612C and 612D, respectively, to provide electrical conductivity between the electrodes and the skin of the patient.
- Adherent patch 600 also comprises a second side, or upper side 610B. In many embodiments, electrodes 612A, 612B, 612C and 612D extend from lower side 610A through adherent patch 100 to upper side 610B.
- adherent patch 100 may comprise a layer of breathable tape 610T, for example a tricot-knit polyester fabric, to allow moisture vapor and air to circulate to and from the skin of the patient through the tape.
- Electrical signals received at electrodes 612A-612D may be communicated to electronic components 630 via flexible connection 622A, which is connected to a PCB (not shown).
- Cover 660 is positioned over batteries 650 and electronic components 630 to provide protection for both.
- flexible cover 662 is positioned to encase the flexible PCB 620, electronics components 630, and/or adherent patch 610 so as to protect at least the electronics components and the PCB
- electronic components 630 may include ECG circuitry utilized to generate electrocardiogram signals and data from two or more of electrodes 612A, 612B, 612C and 612D in many ways.
- ECG circuitry (not shown) is connected to inner electrodes 612B and 612C, which may comprise sense electrodes of the impedance circuitry as described above.
- the ECG circuitry may measure the ECG signal from electrodes 612A and 612D when current is not passed through electrodes 612A and 612D.
- electronic components 630 may include bioimpedance circuitry connected to two or more of electrodes 612A, 612B, 612C and 612D to allow electronic components 630 to measure a bioimpedance associated with the patient.
- electronic components 630 may include an accelerometer configured to measured motion of the patient.
- electronic circuitry 630 may comprise a processor module that can be configured to analyze physiological parameters monitored by adherent device 600 and to control collection and transmission of data from the electrocardiogram circuitry.
- the processor module included as part of electronic circuitry 630 comprises a tangible medium, for example read only memory (ROM), electrically erasable programmable read only memory (EEPROM) and/or random access memory (RAM). Tangible medium may, for example, store heart-rate thresholds to be utilized, as well as rate-based sensitivity levels to be utilized in combination with each heart- rate threshold. Processing of monitored physiological parameters such as ECG signals may be distributed between the local processor module included as part of electronic circuitry 630 and remote monitoring system 106 (shown in FIG. 1).
- a processor and/or a processing module include electronic circuitry configured to process monitored ECG signals of a patient, detect rhythm abnormalities (e.g., bradycardia, tachycardia, etc.) for a plurality of threshold heart rates, capture clinically relevant ECG episode based on the rate-based sensitivity levels associated with each of the plurality of threshold heart rates.
- the processor and/or processing module may also communicate and/or transmit ECG signals and/or captured ECG segments to a remote monitoring center for review by an analysis.
- electronics components 630 comprise wireless communications circuitry (not shown) to communicate with remote center 106.
- the PCB (not shown) may comprise an antenna to facilitate wireless communication.
- the antenna may be integral with the PCB or may be separately coupled thereto.
- the wireless communication circuitry can be coupled to the electrocardiogram circuitry to transmit to a remote center with a communication protocol at least one of the electrocardiogram signal or other features collected by the adherent device 600.
- the wireless communication circuitry is configured to transmit collected physiological parameters to remote center 106 (shown in FIG. 1) either directly or through gateway 102.
- the communication protocol comprises at least one of Bluetooth, ZigBee, WiFi, WiMAX, IR, amplitude modulation or frequency modulation.
- the communications protocol comprises a two-way protocol such that the remote center is capable of issuing commands to control data collection.
- a health care professional (such as a HCP) may push updated heart-rate thresholds and/or rate-based sensitivity levels to adherent device 600.
- a HCP may increase the rate-based sensitivity levels associated with one or more heart-rate thresholds in response to few ECG segments being captured.
- a HCP may decrease the rate-based sensitivity levels associated with one or more heart-rate thresholds.
- FIG. 7 is a perspective view of an insertable monitoring device 700 according to an embodiment of the present invention. In the embodiment shown in FIG.
- insertable cardiac monitor 700 is defined by a length L, a width W and thickness or depth D and is in the form of an elongated rectangular prism wherein the length L is much larger than the width W, which in turn is larger than the depth D.
- the geometry of the insertable cardiac monitor 700 - in particular a width W greater than the depth D - is selected to allow the cardiac monitor 700 to be inserted under the skin of the patient using a minimally invasive procedure and to remain in the desired orientation during insert.
- the device shown in FIG. 7 includes radial asymmetries (notably, the rectangular shape) along the longitudinal axis that maintains the device in the proper orientation following insertion.
- the spacing between proximal electrode 704 and distal electrode 706 may range from 30 millimeters (mm) to 55mm, 35mm to 55mm, and from 40mm to 55mm and may be any range or individual spacing from 25mm to 60mm.
- insertable cardiac monitor 700 may have a length L that ranges from 30mm to about 70mm. In other embodiments, the length L may range from 40mm to 60mm, 45mm to 60mm and may be any length or range of lengths between about 30mm and about 70mm.
- the width W oi major surface 708 may range from 3mm to 10mm and may be any single or range of widths between 3mm and 10mm.
- the thickness of depth D of cardiac monitor device 700 may range from 2mm to 9mm.
- the depth D of insertable cardiac monitor 700 may range from 2mm to 5mm and may be any single or range of depths from 2mm to 9mm.
- insertable cardiac monitor 700 according to an embodiment of the present invention is has a geometry and size designed for ease of implant and patient comfort.
- Embodiments of insertable cardiac monitor 700 described in this disclosure may have a volume of three cubic centimeters (cm) or less, 1.5 cubic cm or less or any volume between three and 1.5 cubic centimeters.
- the first major surface 708 faces outward, toward the skin of the patient while the second major surface 710 is located opposite the first major surface 708.
- proximal end 712 and distal end 714 are rounded to reduce discomfort and irritation to surrounding tissue once inserted under the skin of the patient.
- proximal electrode 704 and distal electrode 706 are used to sense cardiac signals for determining abnormal cardiac events (e.g., bradycardia, tachycardia, etc.).
- ECG signals may be stored in a memory of the insertable cardiac monitor 700, and ECG data may be transmitted via integrated antenna 722 to another medical device, which may be another implantable device or an external device, or to a remote monitoring center.
- electrodes 704 and 706 may be used for sensing any bio-potential signal of interest, which may be, for example, an EGM, EEG, EMG, or a nerve signal, from any implanted location.
- proximal electrode 704 is in close proximity to the proximal end 712 and distal electrode 706 is in close proximity to distal end 714.
- distal electrode 706 is not limited to a flattened, outward facing surface, but may extend from first major surface 708 around rounded edges 716 and onto the second major surface 710 so that the electrode 706 has a three-dimensional curved configuration.
- proximal electrode 704 is located on first major surface 708 and is substantially flat, outward facing.
- proximal electrode 704 may utilize the three dimensional curved configuration of distal electrode 706, providing a three dimensional proximal electrode (not shown in this embodiment).
- distal electrode 706 may utilize a substantially flat, outward facing electrode located on first major surface 708 similar to that shown with respect to proximal electrode 704.
- the various electrode configurations allow for configurations in which proximal electrode 704 and distal electrode 706 are located on both first major surface 708 and second major surface 710. In other configurations, such as that shown in FIG.
- insertable monitoring device 700 may include electrodes on both major surface 708 and 710 at or near the proximal and distal ends of the device, such that a total of four electrodes are included on insertable monitoring device 700.
- Electrodes 704 and 706 may be formed of a plurality of different types of biocompatible conductive material, e.g. stainless steel, titanium, platinum, iridium, or alloys thereof, and may utilize one or more coatings such as titanium nitride or fractal titanium nitride.
- proximal end 712 includes a header assembly 720 that includes one or more of proximal electrode 704, integrated antenna 722, anti-migration projections 724, and/or suture hole 726.
- Integrated antenna 722 is located on the same major surface (i.e., first major surface 708) as proximal electrode 704 and is also included as part of header assembly 720.
- Integrated antenna 722 allows insertable monitoring device 700 to transmit and/or receive data.
- integrated antenna 722 may be formed on the opposite major surface as proximal electrode 704, or may be incorporated within the housing 722 of insertable monitoring device 700.
- electronic circuitry (not shown) may be housed within housing 722. As described above with respect to FIG.
- electronic circuitry may include a tangible medium for storing the plurality of heart-rate thresholds and rate-based sensitivity levels.
- electronic circuitry may include sensing circuitry for sensing one or more physiological parameters, such as ECG signals, accelerometer signals, and/or bio-impedance signals, and may include a processor module for processing monitored ECG signals to detect arrhythmic ECG segments based on the heart-rate thresholds and rate-based sensitivity levels.
- anti-migration projections 724 are located adjacent to integrated antenna 722 and protrude away from first major surface 708 to prevent longitudinal movement of the device.
- anti-migration projections 724 includes a plurality (e.g., nine) small bumps or protrusions extending away from first major surface 708.
- anti-migration projections 724 may be located on the opposite major surface as proximal electrode 704 and/or integrated antenna 722.
- header assembly 720 includes suture hole 726, which provides another means of securing insertable monitoring device 700 to the patient to prevent movement following insert.
- header assembly 720 is a molded header assembly made from a polymeric or plastic material, which may be integrated or separable from the main portion of insertable monitoring device 700.
- the disclosure provides a system and method for monitoring and processing electrocardiogram (ECG) signals to automatically capture clinically relevant ECG segments for subsequent review.
- ECG electrocardiogram
- a method of detecting arrhythmic electrocardiogram (ECG) signals comprises defining a plurality of threshold heart rates and rate-dependent sensitivity levels for detecting arrhythmic ECG episodes, wherein more clinically relevant heart rates are assigned rate-dependent sensitivity levels with higher sensitivities.
- the method may further include monitoring ECG signals associated with a patient using a monitoring device and processing the monitored ECG signals using the plurality of threshold heart rates and rate-dependent sensitivity levels to detect and capture arrhythmic ECG segments.
- the method of the preceding paragraph can optionally include, additionally and/or alternatively any, one or more of the following features, configurations and/or additional components.
- the method may further include wherein the monitoring device processes the monitored ECG signals locally, and wherein captured arrhythmic ECG segments are communicated to a remote monitoring center for review.
- the method may further include wherein monitored ECG signals are communicated to a remote monitoring center for processing of the monitored ECG signals using the plurality of threshold heart rates and rate-dependent sensitivity levels.
- the method may further include wherein the plurality of threshold heart rates include a plurality of heart rate thresholds associated with tachycardia thresholds and a plurality of heart rate thresholds associated with bradycardia thresholds.
- the method may further include wherein higher rate tachycardia thresholds are assigned a higher sensitivity level than lower rate tachycardia thresholds, and lower rate bradycardia thresholds are assigned a higher sensitivity level than higher rate bradycardia thresholds.
- the method may further include wherein the plurality of heart rate thresholds are selected based on one or more patient characteristics.
- the method may further include wherein the one or more patient characteristics include one or more of patient age, weight, sex, and/or basal/resting heart rate.
- the method may further include determining whether the patient is at rest based on one or more physiological parameters and measuring a basal/resting heart rate of the patient in response to a determination that the patient is at rest.
- the method may further include wherein the plurality of threshold heart rates are defined based on the measured basal/resting heart rate.
- the method may further include wherein captured arrhythmic ECG segments are reviewable at a remote monitoring center, wherein the captured arrhythmic ECG segments includes one or more tags that can be utilized to filter and search the plurality of captured arrhythmic ECG segments.
- the method may further include wherein the tags include one or more of a heart- rate threshold that triggered capture of the ECG segment, a rate-based sensitivity level associated with the heart-rate threshold, ratio of beats exceeding the heart-rate threshold, trigger arrhythmic condition, and patient activity level.
- the tags include one or more of a heart- rate threshold that triggered capture of the ECG segment, a rate-based sensitivity level associated with the heart-rate threshold, ratio of beats exceeding the heart-rate threshold, trigger arrhythmic condition, and patient activity level.
- a system for monitoring electrocardiogram (ECG) signals and detecting arrhythmic ECG episodes may include a monitoring device having one or more electrodes and sensing circuitry for monitoring ECG signals associated with a patient and a processing module configured to receive the monitored ECG, wherein the processing module utilizes a plurality of heart-rate thresholds and rate-dependent sensitivity levels to detect and capture arrhythmic ECG segments.
- ECG electrocardiogram
- system of the preceding paragraph can optionally include, additionally and/or alternatively any, one or more of the following features, configurations and/or additional components.
- the processi g module of the system may be included on the monitoring device and may further include memory for storing the plurality of heart-rate thresholds and rate-dependent sensitivity levels and a processor for processing the monitored ECG signals using the heart-rate thresholds and rate-dependent sensitivity levels.
- the processing module of the system may further include wireless communications circuitry for communicating captured ECG segments to a remote monitoring center for review.
- the system may further include wherein the plurality of threshold heart rates include a plurality of heart rate thresholds associated with tachycardia thresholds and a plurality of heart rate thresholds associated with bradycardia thresholds, and wherein higher rate tachycardia thresholds are assigned a higher sensitivity level than lower rate tachycardia thresholds, and lower rate bradycardia thresholds are assigned a higher sensitivity level than higher rate bradycardia thresholds.
- the system may further include wherein the plurality of heart rate thresholds are selected based on one or more patient characteristics, comprising one or more of patient age, weight, sex, and/or basal/resting heart rate.
- the system may further include wherein the processing module determines whether the patient is at rest based on one or more physiological parameters measures a basal/resting heart rate of the patient in response to a determination that the patient is at rest, wherein the plurality of threshold heart rates are defined based on the measured basal/resting heart rate.
- the system may further include wherein the captured arrhythmic ECG segments communicated to a remote monitoring center include one or more tags that can be utilized to filter and search the plurality of captured arrhythmic ECG segments, wherein tags comprise one or more of a heart-rate threshold that triggered capture of the ECG segment, a rate-based sensitivity level associated with the heart-rate threshold, ratio of beats exceeding the heart-rate threshold, trigger arrhythmic condition, and patient activity level.
- tags comprise one or more of a heart-rate threshold that triggered capture of the ECG segment, a rate-based sensitivity level associated with the heart-rate threshold, ratio of beats exceeding the heart-rate threshold, trigger arrhythmic condition, and patient activity level.
- a medical in another embodiment, includes a sensing unit, a memory unit, and a processor.
- the sensing unit is configured to monitor an electrocardiogram (ECG) signal.
- ECG electrocardiogram
- the memory unit is configured to store a plurality of heart-rate thresholds and rate-dependent sensitivity levels
- the processor is configured to process the monitored ECG signal to detect and capture arrhythmic ECG segments based on the plurality of heart-rate thresholds and rate-dependent sensitivity levels.
- the medical device of the preceding paragraph can optionally include, additionally and/or alternatively any, one or more of the following features, configurations and/or additional components.
- the medical device may further include wherein the processing module determines whether the patient is at rest based on one or more physiological parameters measures a basal/resting heart rate of the patient in response to a determination that the patient is at rest, wherein the plurality of threshold heart rates are defined based on the measured basal/resting heart rate.
- the medical device may f urther include wherein the plurality of threshold heart rates include a plurality of heart rate thresholds associated with tachycardia thresholds and a plurality of heart rate thresholds associated with bradycardia thresholds, and wherein higher rate tachycardia thresholds are assigned a higher sensitivity level than lower rate tachycardia thresholds, and lower rate bradycardia thresholds are assigned a higher sensitivity level than higher rate bradycardia thresholds
- the medical device may further include wherein the medical device is one of an adherent device, an implantable device, an insertable device, an injectable device or a wearable device.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Physiology (AREA)
- Dentistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Computer Networks & Wireless Communication (AREA)
- Signal Processing (AREA)
- Primary Health Care (AREA)
- General Business, Economics & Management (AREA)
- Epidemiology (AREA)
- Business, Economics & Management (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Electrotherapy Devices (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201780056278.2A CN109688904B (zh) | 2016-09-28 | 2017-09-27 | 使用基于速率的灵敏度级别进行心脏监测的系统和方法 |
EP17787703.2A EP3518744A1 (en) | 2016-09-28 | 2017-09-27 | System and method for cardiac monitoring using rate-based sensitivity levels |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/278,566 US10143395B2 (en) | 2016-09-28 | 2016-09-28 | System and method for cardiac monitoring using rate-based sensitivity levels |
US15/278,566 | 2016-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018064122A1 true WO2018064122A1 (en) | 2018-04-05 |
Family
ID=60153438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/053635 WO2018064122A1 (en) | 2016-09-28 | 2017-09-27 | System and method for cardiac monitoring using rate-based sensitivity levels |
Country Status (4)
Country | Link |
---|---|
US (1) | US10143395B2 (zh) |
EP (1) | EP3518744A1 (zh) |
CN (1) | CN109688904B (zh) |
WO (1) | WO2018064122A1 (zh) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10852069B2 (en) | 2010-05-04 | 2020-12-01 | Fractal Heatsink Technologies, LLC | System and method for maintaining efficiency of a fractal heat sink |
US11591153B1 (en) * | 2017-02-06 | 2023-02-28 | Rational Packaging Llc | Bifurcated trilobular packaging element |
US11904202B2 (en) | 2019-03-11 | 2024-02-20 | Rom Technolgies, Inc. | Monitoring joint extension and flexion using a sensor device securable to an upper and lower limb |
JP7155061B2 (ja) * | 2019-03-27 | 2022-10-18 | 日本光電工業株式会社 | 生体情報測定装置、不整脈解析システム、不整脈解析方法、不整脈解析プログラム |
US11957956B2 (en) | 2019-05-10 | 2024-04-16 | Rehab2Fit Technologies, Inc. | System, method and apparatus for rehabilitation and exercise |
US12102878B2 (en) | 2019-05-10 | 2024-10-01 | Rehab2Fit Technologies, Inc. | Method and system for using artificial intelligence to determine a user's progress during interval training |
US11904207B2 (en) | 2019-05-10 | 2024-02-20 | Rehab2Fit Technologies, Inc. | Method and system for using artificial intelligence to present a user interface representing a user's progress in various domains |
US11433276B2 (en) | 2019-05-10 | 2022-09-06 | Rehab2Fit Technologies, Inc. | Method and system for using artificial intelligence to independently adjust resistance of pedals based on leg strength |
US11957960B2 (en) | 2019-05-10 | 2024-04-16 | Rehab2Fit Technologies Inc. | Method and system for using artificial intelligence to adjust pedal resistance |
US11446505B2 (en) * | 2019-05-31 | 2022-09-20 | Cardiac Pacemakers, Inc. | His-bundle pacing for atrioventricular block |
US11896540B2 (en) | 2019-06-24 | 2024-02-13 | Rehab2Fit Technologies, Inc. | Method and system for implementing an exercise protocol for osteogenesis and/or muscular hypertrophy |
US11071597B2 (en) | 2019-10-03 | 2021-07-27 | Rom Technologies, Inc. | Telemedicine for orthopedic treatment |
US12020799B2 (en) | 2019-10-03 | 2024-06-25 | Rom Technologies, Inc. | Rowing machines, systems including rowing machines, and methods for using rowing machines to perform treatment plans for rehabilitation |
US11069436B2 (en) | 2019-10-03 | 2021-07-20 | Rom Technologies, Inc. | System and method for use of telemedicine-enabled rehabilitative hardware and for encouraging rehabilitative compliance through patient-based virtual shared sessions with patient-enabled mutual encouragement across simulated social networks |
US12020800B2 (en) | 2019-10-03 | 2024-06-25 | Rom Technologies, Inc. | System and method for using AI/ML and telemedicine to integrate rehabilitation for a plurality of comorbid conditions |
US11961603B2 (en) | 2019-10-03 | 2024-04-16 | Rom Technologies, Inc. | System and method for using AI ML and telemedicine to perform bariatric rehabilitation via an electromechanical machine |
US11955220B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using AI/ML and telemedicine for invasive surgical treatment to determine a cardiac treatment plan that uses an electromechanical machine |
US11955223B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using artificial intelligence and machine learning to provide an enhanced user interface presenting data pertaining to cardiac health, bariatric health, pulmonary health, and/or cardio-oncologic health for the purpose of performing preventative actions |
US11978559B2 (en) | 2019-10-03 | 2024-05-07 | Rom Technologies, Inc. | Systems and methods for remotely-enabled identification of a user infection |
US11075000B2 (en) | 2019-10-03 | 2021-07-27 | Rom Technologies, Inc. | Method and system for using virtual avatars associated with medical professionals during exercise sessions |
US11887717B2 (en) | 2019-10-03 | 2024-01-30 | Rom Technologies, Inc. | System and method for using AI, machine learning and telemedicine to perform pulmonary rehabilitation via an electromechanical machine |
US11955222B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for determining, based on advanced metrics of actual performance of an electromechanical machine, medical procedure eligibility in order to ascertain survivability rates and measures of quality-of-life criteria |
US11915816B2 (en) | 2019-10-03 | 2024-02-27 | Rom Technologies, Inc. | Systems and methods of using artificial intelligence and machine learning in a telemedical environment to predict user disease states |
US11101028B2 (en) | 2019-10-03 | 2021-08-24 | Rom Technologies, Inc. | Method and system using artificial intelligence to monitor user characteristics during a telemedicine session |
US12062425B2 (en) | 2019-10-03 | 2024-08-13 | Rom Technologies, Inc. | System and method for implementing a cardiac rehabilitation protocol by using artificial intelligence and standardized measurements |
US11915815B2 (en) | 2019-10-03 | 2024-02-27 | Rom Technologies, Inc. | System and method for using artificial intelligence and machine learning and generic risk factors to improve cardiovascular health such that the need for additional cardiac interventions is mitigated |
US11317975B2 (en) | 2019-10-03 | 2022-05-03 | Rom Technologies, Inc. | Method and system for treating patients via telemedicine using sensor data from rehabilitation or exercise equipment |
US11955221B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using AI/ML to generate treatment plans to stimulate preferred angiogenesis |
US11923065B2 (en) | 2019-10-03 | 2024-03-05 | Rom Technologies, Inc. | Systems and methods for using artificial intelligence and machine learning to detect abnormal heart rhythms of a user performing a treatment plan with an electromechanical machine |
US11278233B2 (en) * | 2019-11-15 | 2022-03-22 | Biosense Webster (Israel) Ltd. | Method and apparatus to find abnormal activations in intra-cardiac electrocardiograms based on specificity and sensitivity |
US11107591B1 (en) | 2020-04-23 | 2021-08-31 | Rom Technologies, Inc. | Method and system for describing and recommending optimal treatment plans in adaptive telemedical or other contexts |
US11602313B2 (en) * | 2020-07-28 | 2023-03-14 | Medtronic, Inc. | Determining a fall risk responsive to detecting body position movements |
US12100499B2 (en) | 2020-08-06 | 2024-09-24 | Rom Technologies, Inc. | Method and system for using artificial intelligence and machine learning to create optimal treatment plans based on monetary value amount generated and/or patient outcome |
US11877855B2 (en) * | 2020-08-20 | 2024-01-23 | Atsens Co., Ltd. | Apparatus for measuring electrocardiogram and method of recording ECG signals merged with user input |
EP3960082A1 (en) * | 2020-08-27 | 2022-03-02 | Atsens Co., Ltd. | Apparatus for measuring electrocardiogram and method of recording ecg signals merged with user input |
US20240055116A1 (en) * | 2022-08-10 | 2024-02-15 | Honeywell International Inc. | Apparatuses, computer-implemented methods, and computer program products for improved health monitor data monitoring |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1114653A2 (en) * | 2000-01-05 | 2001-07-11 | Pacesetter, Inc. | An implantable cardioversion device with a self-adjusting threshold for therapy selection |
US20070213599A1 (en) * | 2006-03-13 | 2007-09-13 | Siejko Krzysztof Z | Physiological event detection systems and methods |
US20110257535A1 (en) * | 2010-04-15 | 2011-10-20 | CardGuard | System and a method for cardiac monitoring |
WO2015066430A1 (en) * | 2013-11-01 | 2015-05-07 | Medtronic Monitoring, Inc. | Congestive heart failure risk status determination methods and related devices |
US20160045131A1 (en) * | 2014-08-18 | 2016-02-18 | Cameron Health, Inc. | Cardiac rate tracking in an implantable medical device |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4830006B1 (en) | 1986-06-17 | 1997-10-28 | Intermedics Inc | Implantable cardiac stimulator for detection and treatment of ventricular arrhythmias |
US4940054A (en) | 1988-04-29 | 1990-07-10 | Telectronics N.V. | Apparatus and method for controlling multiple sensitivities in arrhythmia control system including post therapy packing delay |
US5607460A (en) | 1996-03-15 | 1997-03-04 | Angeion Corporation | Physician interface expert system for programming implantable arrythmia treatment devices |
DE60102836T2 (de) | 2000-11-28 | 2005-04-21 | Medtronic Inc | Vorrichtung zur erkennung einer vorhoffibrillation mittels herzkammerdetektion |
US6895272B2 (en) * | 2001-04-06 | 2005-05-17 | Cardiac Pacemakers, Inc. | Atrial tachyarrhythmia detection system and method |
US6625490B1 (en) | 2001-11-14 | 2003-09-23 | Pacesetter, Inc. | System and method of automatically adjusting sensing parameters based on temporal measurement of cardiac events |
US7330757B2 (en) * | 2001-11-21 | 2008-02-12 | Cameron Health, Inc. | Method for discriminating between ventricular and supraventricular arrhythmias |
US7031765B2 (en) | 2002-11-11 | 2006-04-18 | Medtronic, Inc | Algorithms for detecting atrial arrhythmias from discriminatory signatures of ventricular cycle lengths |
US7447544B1 (en) | 2004-02-18 | 2008-11-04 | Pacesetter, Inc. | System and method for controlling the recording of diagnostic medical data in an implantable medical device |
US8326407B2 (en) | 2004-10-19 | 2012-12-04 | University Of Washington | Long-term monitoring for discrimination of different heart rhythms |
US7280869B2 (en) | 2004-12-03 | 2007-10-09 | Medtronic, Inc. | Arrhythmia termination detection based on beat pattern |
US8725258B2 (en) | 2006-08-25 | 2014-05-13 | Cardiac Pacemakers, Inc. | Method and apparatus for automated adjustment of arrhythmia detection duration |
US7634310B2 (en) | 2006-10-30 | 2009-12-15 | Medtronic, Inc. | Method and apparatus for atrial fibrillation detection based on ventricular cycle lengths |
US8175708B1 (en) | 2006-12-07 | 2012-05-08 | Pacesetter, Inc. | System and method for adjusting automatic sensitivity control parameters based on intracardiac electrogram signals |
US8249707B2 (en) | 2008-05-14 | 2012-08-21 | Pacesetter, Inc. | Methods and systems for improved arrhythmia discrimination |
US8790259B2 (en) | 2009-10-22 | 2014-07-29 | Corventis, Inc. | Method and apparatus for remote detection and monitoring of functional chronotropic incompetence |
US8965498B2 (en) | 2010-04-05 | 2015-02-24 | Corventis, Inc. | Method and apparatus for personalized physiologic parameters |
JP5922103B2 (ja) * | 2010-05-18 | 2016-05-24 | ゾール メディカル コーポレイションZOLL Medical Corporation | 複数の検知電極を備えた着用可能な携行型医療装置 |
US20120101392A1 (en) | 2010-10-26 | 2012-04-26 | Medtronic, Inc. | Optimization of arrhythmia detection based on patient activity |
FR2982773A1 (fr) | 2011-11-22 | 2013-05-24 | Sorin Crm Sas | Dispositif medical de type defibrillateur/cardioverteur implantable avec seuil de detection ventriculaire ajustable dynamiquement |
US9427165B2 (en) | 2012-03-02 | 2016-08-30 | Medtronic Monitoring, Inc. | Heuristic management of physiological data |
US20130237872A1 (en) * | 2012-03-12 | 2013-09-12 | Xusheng Zhang | Heart sound sensing to reduce inappropriate tachyarrhythmia therapy |
US8897863B2 (en) | 2012-05-03 | 2014-11-25 | University Of Washington Through Its Center For Commercialization | Arrhythmia detection using hidden regularity to improve specificity |
US9314178B2 (en) | 2013-03-14 | 2016-04-19 | Greatbach, Ltd. | Cardiac signal recording using dynamically generated detection thresholds |
US9744364B2 (en) | 2013-09-25 | 2017-08-29 | Medtronic, Inc. | Method and apparatus for automatic configuration of implantable medical devices |
US9656091B2 (en) | 2014-07-11 | 2017-05-23 | Cardiac Pacemakers, Inc. | Power saving communication for medical devices |
US9986932B2 (en) | 2014-11-17 | 2018-06-05 | Medtronic Monitoring, Inc. | QT interval determination methods and related devices |
CN105943021B (zh) * | 2016-05-13 | 2018-09-21 | 赵伟 | 一种可穿戴心脏节律监测装置和心律监测系统 |
-
2016
- 2016-09-28 US US15/278,566 patent/US10143395B2/en active Active
-
2017
- 2017-09-27 EP EP17787703.2A patent/EP3518744A1/en active Pending
- 2017-09-27 CN CN201780056278.2A patent/CN109688904B/zh active Active
- 2017-09-27 WO PCT/US2017/053635 patent/WO2018064122A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1114653A2 (en) * | 2000-01-05 | 2001-07-11 | Pacesetter, Inc. | An implantable cardioversion device with a self-adjusting threshold for therapy selection |
US20070213599A1 (en) * | 2006-03-13 | 2007-09-13 | Siejko Krzysztof Z | Physiological event detection systems and methods |
US20110257535A1 (en) * | 2010-04-15 | 2011-10-20 | CardGuard | System and a method for cardiac monitoring |
WO2015066430A1 (en) * | 2013-11-01 | 2015-05-07 | Medtronic Monitoring, Inc. | Congestive heart failure risk status determination methods and related devices |
US20160045131A1 (en) * | 2014-08-18 | 2016-02-18 | Cameron Health, Inc. | Cardiac rate tracking in an implantable medical device |
Also Published As
Publication number | Publication date |
---|---|
EP3518744A1 (en) | 2019-08-07 |
CN109688904A (zh) | 2019-04-26 |
CN109688904B (zh) | 2023-03-28 |
US20180085021A1 (en) | 2018-03-29 |
US10143395B2 (en) | 2018-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10143395B2 (en) | System and method for cardiac monitoring using rate-based sensitivity levels | |
US8688189B2 (en) | Programmable ECG sensor patch | |
EP2257216B1 (en) | Heart failure decompensation prediction based on cardiac rhythm | |
US9173615B2 (en) | Method and apparatus for personalized physiologic parameters | |
US10321823B2 (en) | System and method to flag arrhythmia episodes for urgent review | |
WO2008005015A1 (en) | Programmable ecg sensor patch | |
US11576605B2 (en) | System and method for onset/offset capture | |
US9636069B2 (en) | System and method for monitoring and classifying atrial fibrillations | |
US10335053B2 (en) | System and method for cardiac monitoring using adaptive sensitivity/specificity levels | |
US10542939B2 (en) | System and methods of processing accelerometer signals | |
US20090137890A1 (en) | Devices to monitor glucose levels and ischemia | |
WO2010104978A2 (en) | System and method for delivery of physician notifications | |
CN116133581A (zh) | 响应于检测到身体位置移动来确定跌倒风险 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17787703 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017787703 Country of ref document: EP Effective date: 20190429 |